Demonstration of mixed properties of ru486 in progesterone receptor (pr)-transfected mda-mb-231 cells: A model for studying the functions of progesterone analogues

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 1978-1986

  Lin, V C L ^a   Aw, S E ^a   Ng, E H ^a   Ng, E H L ^a   Tan, M G K ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

p44 MAPK PR transfected MDA MB 231; RU486 morphology cell growth p42

Indexed keywords

MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; ONAPRISTONE; PROGESTERONE; PROTEIN P44;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; ENZYME ACTIVATION; FOCAL ADHESION; GENETIC TRANSFECTION; MITOSIS INHIBITION; MOLECULAR GENETICS; PRIORITY JOURNAL; STELLATE CELL;

BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CELL SIZE; ENZYME ACTIVATION; FEMALE; FOCAL ADHESIONS; GONANES; HORMONE ANTAGONISTS; HUMANS; MAP KINASE SIGNALING SYSTEM; MIFEPRISTONE; PROGESTERONE; RECEPTORS, PROGESTERONE; RECOMBINANT FUSION PROTEINS; STRESS FIBERS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0035556132     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2167     Document Type: Article

References (29)

1. Two types of antiprogestins have distinct effects on site-specific phosphorylation of human progesterone receptor
2. Type II antagonists impair the DNA binding of steroid hormone receptors without affecting dimerization
3. RU486 (Mifepristone): Mechanisms of action and clinical uses
4. Reproductive functions of the progesterone receptor lessens from knock-out mice
5. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio-and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity
6. Human progesterone receptor complexed with the antagonist RU 486 binds to hormone response elements in a structurally altered form
7. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist
8. Clinical use of RU 486: Control of the menstrual cycle and effect on the hypophyseal-adrenal axis
9. Endometrial and pituitary responses to the steroidal antiprogestin RU486 in postmenopausal women
10. Receptors bound to antiprogestin from abortive complexes with hormone responsive elements
11. Rho GTPases and the actin cytoskeleton
12. The effects of an antiprogesterone steroid in women: Interruption of the menstrual cycle and of early pregnancy
13. Novel mechanisms of antiprogestin action
14. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/Spa and the corepressors N-CoR or SMRT
15. Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms
16. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells
17. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA
18. Progesterone induces cell spreading and focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor cDNA
19. Agonistic and antagonist activities of RU486 on the function of the human progesterone receptor
20. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A
21. Phase II study of Mifepristone (RU486) in refactory ovarian cancer
22. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: Only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP
23. Development of anticancer drugs targeting the MAP kinase pathway
24. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
25. Progesterone receptor modulators and progesterone antagonists in women's health
26. Tamoxifen resistant breast cancer: Coregulators determine the direction of transcription by antagonist-occupied steroid receptors
27. Antiprogestins prevent progesterone receptor binding to hormone response elements in vivo
28. Antagonist occupied human progesterone B-receptors activate transcription without binding to progesterone response elements, and are dominantly inhibited by A-receptors
29. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis